Edition:
India

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

9.99USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$9.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,284
52-wk High
$10.20
52-wk Low
$3.20

Select another date:

Fri, Feb 16 2018

BRIEF-Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period

* SEATTLE GENETICS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD

BRIEF-Seattle Genetics Commences Tender Offer For Cascadian Therapeutics

* SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC.

BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million

* SEATTLE GENETICS SAYS IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CASCADIAN THERAPEUTICS MAY BE REQUIRED TO PAY CO FEE OF $17 MILLION - SEC FILING Source text: (http://bit.ly/2E2RNXK) Further company coverage:

BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics

* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE

BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency

* CASCADIAN THERAPEUTICS RECEIVES PEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

Select another date: